Abstract
The Council for International Organizations of Medical Sciences (CIOMS) III working group has published a report attempting to harmonize and set criteria for drug labeling. The group identified and ranked 39 criteria to determine the threshold for adding adverse events to the labeling of marketed drugs. A survey was taken in several departments of the Schering Corporation to determine whether these criteria would be ranked in a similar manner. The results showed that there was a high degree of correlation in the rankings (0.79) with the greatest correlation being seen in the drug safety groups both in the United States-based home office (0.88) and in the non-United States subsidiaries (0.74). It is concluded that there is a large degree of agreement between the criteria for addition of adverse events to product labeling proposed by the CIOMS group and at least one major pharmaceutical company.
Similar content being viewed by others
References
US Code of Federal Regulations section 201.
Hollister, L. Editorial: New ideas about drug labels. Clin Pharm Ther. 1973; 14:309–313.
Karen, F, Lasagna, L. Adverse drug reactions—a critical review. JAMA. 1975; 234:1236–1241.
Naranjo, C, Shear, N, Lanctot, K. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol. 1992; 32:897–904.
Guidelines for Preparing Core Clinical-Safety Information on Drugs. Report of CIOMS Working Group III, Geneva, 1995.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cobert, B.L. The CIOMS III Criteria for Labeling Changes: A Survey at Schering-Plough. Ther Innov Regul Sci 32, 1149–1151 (1998). https://doi.org/10.1177/009286159803200435
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286159803200435